Home » Alnylam, European Patent Office, Invitrogen, Merck, Integra, Qiagen

Alnylam, European Patent Office, Invitrogen, Merck, Integra, Qiagen

Jun 17, 2005
Premium

Alnylam Says European Patent Office Issues
Patent On RNAi Technology Licensed by Company

Alnylam Pharmaceuticals said this week that the European Patent Office has issued a patent on technology, to which the company holds an exclusive license, related to the therapeutic use of double-stranded RNA expressed from endogenous templates or expression vectors to mediate RNA interference.

Alnylam said that it holds the rights to the patent under an agreement with Cancer Research Technology Limited.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Embryos Edited in US

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

True Blue

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

All the Plants

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

This Week in Nature

In Nature this week: a Danish reference genome, and more.

What's Popular?

In Gene Silencing/Gene Editing

  1. Cancer Dependency Maps Developed by Two Research Teams

  2. UPDATE: CRISPR Stakeholders Seek Reversal of Patent Interference Proceeding Decision

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.